These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33289503)

  • 1. Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
    Riva M; Wouters R; Sterpin E; Giovannoni R; Boon L; Himmelreich U; Gsell W; Van Ranst M; Coosemans A
    Neurosurgery; 2021 Jan; 88(2):E205-E215. PubMed ID: 33289503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8
    Liu F; Zhou Q; Jiang HF; Zhang TT; Miao C; Xu XH; Wu JX; Yin SL; Xu SJ; Peng JY; Gao PP; Cao X; Pan F; He X; Chen XQ
    J Exp Clin Cancer Res; 2023 May; 42(1):118. PubMed ID: 37161450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
    Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
    BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation dose-escalation and dose-fractionation modulate the immune microenvironment, cancer stem cells and vasculature in experimental high-grade gliomas.
    Riva M; Wouters R; Nittner D; Ceusters J; Sterpin E; Giovannoni R; Himmelreich U; Gsell W; VAN Ranst M; Coosemans A
    J Neurosurg Sci; 2023 Feb; 67(1):55-65. PubMed ID: 33056947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging temozolomide-induced changes in the myeloid glioma microenvironment.
    Foray C; Valtorta S; Barca C; Winkeler A; Roll W; Müther M; Wagner S; Gardner ML; Hermann S; Schäfers M; Grauer OM; Moresco RM; Zinnhardt B; Jacobs AH
    Theranostics; 2021; 11(5):2020-2033. PubMed ID: 33500706
    [No Abstract]   [Full Text] [Related]  

  • 6. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
    Ashby LS; Smith KA; Stea B
    World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
    Banissi C; Ghiringhelli F; Chen L; Carpentier AF
    Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
    Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
    Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
    Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
    Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
    He Y; Kaina B
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells.
    Hasan MN; Luo L; Ding D; Song S; Bhuiyan MIH; Liu R; Foley LM; Guan X; Kohanbash G; Hitchens TK; Castro MG; Zhang Z; Sun D
    Theranostics; 2021; 11(3):1295-1309. PubMed ID: 33391535
    [No Abstract]   [Full Text] [Related]  

  • 13. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
    Dai B; Qi N; Li J; Zhang G
    Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
    Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
    J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
    Wang J; Wang Y; He Y; Guan H; He L; Mu X; Peng X
    Trials; 2019 Nov; 20(1):641. PubMed ID: 31752981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
    Sanchez-Perez LA; Choi BD; Archer GE; Cui X; Flores C; Johnson LA; Schmittling RJ; Snyder D; Herndon JE; Bigner DD; Mitchell DA; Sampson JH
    PLoS One; 2013; 8(3):e59082. PubMed ID: 23527092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
    Wick A; Desjardins A; Suarez C; Forsyth P; Gueorguieva I; Burkholder T; Cleverly AL; Estrem ST; Wang S; Lahn MM; Guba SC; Capper D; Rodon J
    Invest New Drugs; 2020 Oct; 38(5):1570-1579. PubMed ID: 32140889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
    Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
    J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.